Ozoralizumab, a Humanized Anti-TNFα NANOBODY(®) Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an Anti-TNFα IgG

Although the introduction of tumor necrosis factor (TNF) inhibitors represented a significant advance in the treatment of rheumatoid arthritis (RA), traditional anti-TNFα antibodies are somewhat immunogenic, and their use results in the formation of anti-drug antibodies (ADAs) and loss of efficacy (...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishiwatari-Ogata, Chihiro, Kyuuma, Masanao, Ogata, Hitoshi, Yamakawa, Machi, Iwata, Katsuya, Ochi, Motoki, Hori, Miyuki, Miyata, Noriyuki, Fujii, Yasuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902368/
https://www.ncbi.nlm.nih.gov/pubmed/35273620
http://dx.doi.org/10.3389/fimmu.2022.853008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902368/
https://www.ncbi.nlm.nih.gov/pubmed/35273620
http://dx.doi.org/10.3389/fimmu.2022.853008

Ejemplares similares